|
|
Cat. No. 471 203 |
50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
Applications | |
Immunogen | Synthetic peptide comprising almost all of the processed mouse GLP-2 (UniProt Id: P55095) |
Reactivity |
Reacts with: mouse (P55095), rat (P06883). Other species not tested yet. |
Specificity | The antibody recognizes GLP-2. It may show cross-reactivity with the unprocessed precursor protein, but it does not detect GLP-1. |
Remarks |
Dot blot: This application was tested with synthetic peptides only. |
Data sheet | 471_203.pdf |
|
Glucagon-like peptide-2 (GLP-2) is a 33-amino acid peptide generated by tissue-specific posttranslational processing of the proglucagon precursor. It is primarily secreted by enteroendocrine L cells located in the distal small intestine and colon, and in much smaller quantities from certain neurons in the brainstem and the hypothalamus. Its secretion is stimulated by nutrient ingestion, especially fats and carbohydrates (1-3).
GLP-2 exerts its effects via interaction with its specific G-protein-coupled receptor GLP-2R (1). GLP-2R can couple to different G-protein subunits to activate multiple signalling pathways (4).
The actions of GLP-2 in the gastrointestinal tract include promotion of intestinal growth, stimulation of nutrient absorption, improvement in intestinal barrier function and suppression of gastric emptying. Further, GLP-2 increases intestinal blood flow, and it has anti-inflammatory effects (3,4).
GLP-2 has been identified as a promising target for gastrointestinal diseases, such as short bowel syndrome (SBS), inflammatory bowel disease, and chemotherapy-induced mucositis, and GLP-2 analogues have been developed for treatment of SBS (1-4).